Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Halozyme Therapeutics Inc (NASDAQ: HALO) closed at $67.27 in the last session, up 2.64% from day before closing price of $65.54. In other words, the price has increased by $2.64 from its previous closing price. On the day, 1.67 million shares were traded. HALO stock price reached its highest trading level at $67.395 during the session, while it also had its lowest trading level at $65.77.
Ratios:
We take a closer look at HALO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.35 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.55. For the most recent quarter (mrq), Quick Ratio is recorded 7.01 and its Current Ratio is at 8.36. In the meantime, Its Debt-to-Equity ratio is 4.54 whereas as Long-Term Debt/Eq ratio is at 4.54.
Morgan Stanley Downgraded its Overweight to Equal-Weight on May 14, 2025, while the target price for the stock was maintained at $62.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 13 ’25 when Torley Helen sold 20,000 shares for $64.32 per share. The transaction valued at 1,286,351 led to the insider holds 733,719 shares of the business.
Torley Helen sold 20,000 shares of HALO for $1,270,121 on Aug 12 ’25. The PRESIDENT AND CEO now owns 733,719 shares after completing the transaction at $63.51 per share. On Aug 11 ’25, another insider, Torley Helen, who serves as the PRESIDENT AND CEO of the company, sold 20,000 shares for $63.05 each. As a result, the insider received 1,260,917 and left with 733,719 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 7868302336 and an Enterprise Value of 8858195968. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.37, and their Forward P/E ratio for the next fiscal year is 8.61. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.48. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.68 while its Price-to-Book (P/B) ratio in mrq is 23.78. Its current Enterprise Value per Revenue stands at 7.515 whereas that against EBITDA is 11.677.
Stock Price History:
The Beta on a monthly basis for HALO is 1.19, which has changed by 0.08956921 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, HALO has reached a high of $70.50, while it has fallen to a 52-week low of $42.01. The 50-Day Moving Average of the stock is 17.87%, while the 200-Day Moving Average is calculated to be 19.86%.
Shares Statistics:
According to the various share statistics, HALO traded on average about 2.16M shares per day over the past 3-months and 2375160 shares per day over the past 10 days. A total of 117.62M shares are outstanding, with a floating share count of 115.67M. Insiders hold about 1.10% of the company’s shares, while institutions hold 100.62% stake in the company. Shares short for HALO as of 1753920000 were 9932500 with a Short Ratio of 4.59, compared to 1751241600 on 10176028. Therefore, it implies a Short% of Shares Outstanding of 9932500 and a Short% of Float of 11.8599996.
